approval of Aarti Drugs Limited Performance Stock Option Plan 2026

Ref: ADL/SE/2026-27/40 August 27, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sub: Outcome of the Board Meeting This is to inform you that the Board of Directors of the Company at its Meeting held today i.e. Thursday, August 27, 2026, inter-alia, considered and approved the “Aarti Drugs Limited Performance Stock Option Plan 2026” ('PSOP 2026'/ 'Plan') to create and grant not exceeding 8,00,000 (Eight lakh) Performance Stock Options convertible into equal number of equity shares of face value of Rs. 10/- each to the eligible employees as per the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, subject to the approval of the Members of the Company. The Meeting of the Board of Directors commenced at 11:30 AM and concluded at 12:20 PM. Kindly take the same on record. Thanking you. Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932